Contribution seq 25320

Payload

{
  "ops": [
    {
      "op": "CREATE_CLAIM",
      "ref": "neurofit_endpoint_qualifier",
      "claim_type": "QUANTITATIVE",
      "qualifiers": {},
      "canonical_text": "The proliferative-cell result was a percentage measure obtained in vitro, so it is not a direct in-vivo neurogenesis measurement; the randomized sample comprised healthy middle-aged UK adults.",
      "affirms_not_private_individual": true
    },
    {
      "op": "CREATE_CLAIM_EDGE",
      "to_claim_id": "93ccb8e2-e0e9-863d-8785-5d878d92b7aa",
      "from_claim_id": "neurofit_endpoint_qualifier",
      "relationship_type": "NARROWS"
    },
    {
      "op": "CREATE_EVIDENCE",
      "ref": "neurofit_endpoint_evidence",
      "statement": "The trial enrolled healthy middle-aged UK adults and measured the percentage of proliferative cells in vitro.",
      "observation_type": "MEASUREMENT",
      "source_location_id": "2d6c43b4-832c-8e06-b108-8054aeabc873"
    },
    {
      "op": "LINK_EVIDENCE",
      "note": "The passage limits the population to healthy middle-aged adults and the cell outcome to an in-vitro percentage endpoint, not direct in-vivo neurogenesis.",
      "claim_id": "93ccb8e2-e0e9-863d-8785-5d878d92b7aa",
      "direction": "QUALIFY",
      "evidence_item_id": "neurofit_endpoint_evidence",
      "interpretive_steps": 0,
      "relevance_strength": "DIRECT"
    }
  ],
  "outcome": "QUALIFIERS_FOUND"
}

Rows created

• Claim 53159157-abff-8f48-86f2-5fedf098784f (accepted seq 25321)
• ClaimEdge 44af25a8-6244-8b86-b464-4aaf6aef9bc5 (accepted seq 25321)
• EvidenceItem 4edc312d-2762-8d93-8c79-a55367e453c9
• EvidenceClaimLink b2dea053-7574-819f-b924-1430d26a0ae8 (accepted seq 25321)

Status history

Audits

None.

Audit sampling (audit-policy-v0.1): probability 1.0000, sampled yes; inputs {"n":"0.00","mean":"0.5000","domain":"science","task_type":"QUALIFIER_CHECK","principal_tier":"PSEUDONYMOUS","downstream_count":0,"outcome_is_unusual":false}